Veloxis Pharmaceuticals Announces Financial Results for the First Nine Months of 2016 and Provides Corporate Update


Highlights 

·        Envarsus XR reaches an estimated 1,200 patients on therapy in the U.S. and an estimated 2,000 patients in EU countries

·        Total net revenues for Veloxis grew 27% in the third quarter of 2016 over the second quarter of 2016 as launch activities for Envarsus XR in the U.S. continue to increase the number of transplant centers, new prescribers, and patients

In connection with the financial report, Veloxis President and CEO, Craig A. Collard, said:

“We continue to be pleased with the response to Envarsus XR in the U.S.  There is a steady upward trajectory for key metrics as we work to establish Envarsus XR as a valuable option for treating kidney transplant patients with tacrolimus.”

 

Summary

Net revenue for the third quarter of 2016 totaled 2,239 tUSD compared with 1,767 tUSD in the second quarter of 2016, as the company continues the launch of Envarsus XR in the U.S.  Veloxis reported a net loss of 7,554 tUSD for the third quarter of 2016 compared to a net loss of 9,298 tUSD for the second quarter of 2016 and 7,300 tUSD for the third quarter of 2015. 

 

Outlook for 2016

Veloxis maintains its 2016 outlook of an operating loss and net loss of USD 25.0 – 31.0 Million, as noted in the Interim Report for the period 1 January to 30 June 2016.

 

Conference Call

A conference call will be held tomorrow, 17 November 2016 at 3:00 PM CEST (Denmark); 2:00 PM GMT (London); 9:00 AM EST (New York).

To access the live conference call, please dial one of the following numbers:

Confirmation Code: 3090135

UK: +44(0)20 3427 1903

US: +1 212 444 0895

DK: +4532 71 16 59

Following the conference call, a recording will be available on the company’s website http://www.veloxis.com.

 

 


Attachments

Veloxis 2016 Q3 Interim Report - 16 November 2016.pdf